The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behaviour and Diet is a comprehensive reference to the aspects, features and effects of depression. This book provides readers with the behavior and psychopathological effects of depression, linking anxiety, anger and PSTD to depression. Readers are provided with a detailed outline of the genetic aspects of depression including synaptic genes and the genome-wide association studies (GWAS) of depression, followed by a thorough analysis of the neurological and imaging techniques used to study depression. This book also includes three full sections on the various effects of depression, including diet, nutrition and molecular and cellular effects. The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behaviour and Diet is the only resource for researchers and practitioners studying depression.
The Neuroscience of Depression: Features, Diagnosis and Treatment
The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behaviour and Diet
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Contributors for Volume 1 - p. xix 7. Foreword for Volume 1 - p. xxv 8. Preface for Volume 1 - p. xxvi 9. Copyright - p. xxvi 10. Contributors for Volume 2 - p. xvii 11. Foreword for Volume 2 - p. xviii 12. Preface for Volume 1 - p. xxiv 13. Part I: Depression: Introductory chapters - p. xxiv 14. Chapter 1. Clinical staging in depression - p. 8 15. Chapter 2. Neurodevelopmental theory of depression - p. 13 16. Chapter 3. Depression after pregnancy - p. 21 17. Chapter 4. Modeling maternal depression during pregnancy: Rodent models of major depressive disorder with peripartum onset - p. 33 18. Chapter 5. Depression in mothers and mental health in their children: Impact, risk factors, and interventions - p. 45 19. Chapter 6. The neuroscience of depression: Mechanisms and treatments - p. 57 20. Chapter 7. Depression in disasters and traumatic events - p. 72 21. Chapter 8. Depression and associated Alzheimer’s disease - p. 79 22. Chapter 9. Comorbidities of depression and Parkinson’s disease - p. 89 23. Chapter 10. Understanding the relationship between depression and alcohol among students - p. 101 24. Chapter 11. Depression in obesity - p. 115 25. Chapter 12. Heart rate variability and depression - p. 121 26. Chapter 13. Neuroinflammation and depression - p. 131 27. Chapter 14. Interlinking antidepressants and the immune system - p. 143 28. Part II: Biomarkers and diagnosis - p. 151 29. Chapter 15. Assessment scoring tools of depression - p. 155 30. Chapter 16. The Beck depression inventory: Uses and applications - p. 165 31. Chapter 17. Hamilton depression rating scale: Uses and applications - p. 176 32. Chapter 18. The patient health questionnaire (PHQ) - p. 185 33. Chapter 19. Screening for antenatal depression (AND) using self-report questionnaires: Conceptual issues and measurement limitations - p. 195 34. Chapter 20. Edinburgh postnatal depression scale: Description and applications - p. 205 35. Chapter 21. The death depression scale: Description and applications - p. 211 36. Chapter 22. The Depression Anxiety Stress Scale: Features and applications - p. 219 37. Chapter 23. Arabic version of the two-question quick inventory of depression (QID-2-AR): Description and applications - p. 229 38. Chapter 24. Depression and biomarkers of cardiovascular disease - p. 239 39. Chapter 25. Thioredoxin as an antioxidant protein as a marker in depression - p. 249 40. Chapter 26. Methods of neuroimaging in depression: Applications to resting-state functional connectivity - p. 264 41. Chapter 27. Neural markers of depression in MRI - p. 271 42. Part III: Pharmacological treatments for depression - p. 279 43. Chapter 28. Angiotensin receptor 1 blockade as an antidepression strategy - p. 283 44. Chapter 29. The link between cannabinoids and depression - p. 293 45. Chapter 30. Agomelatine: Profile and applications to depression - p. 301 46. Chapter 31. Bumetanide and use in depressive states - p. 309 47. Chapter 32. Linking citalopram, serotonin reuptake inhibitors, and depressed pregnant women - p. 325 48. Chapter 33. Citalopram and its use in sleep-deprivation-induced depression - p. 337 49. Chapter 34. Monoaminergic system and antidepressants - p. 345 50. Chapter 35. Duloxetine usage in depression - p. 357 51. Chapter 36. Escitalopram and blonanserin as antidepressant agents linking in neurotrophic mechanisms - p. 369 52. (2R,6R)-Hydroxynorketamine as a novel antidepressant and its role in the antidepressant actions of (R,S)-ketamine - p. 385 53. Linking 5-hydroxytryptamine to antidepressant actions of (R)-ketamine and social stress model - p. 393 54. Chapter 39. Mirtazapine: Multitarget strategies for treating substance use disorder and depression - p. 401 55. Part IV: Counselling, psychotherapy and behavioural treatments for depression - p. 410 56. Chapter 40. Mindfulness-based cognitive therapy and depression - p. 413 57. Chapter 41. Online programs for depression - p. 423 58. Chapter 42. Clay art therapy on emotion regulation: Research, theoretical underpinnings, and treatment mechanisms - p. 431 59. Chapter 43. Solution-focused counseling and its use in postpartum depression - p. 443 60. Chapter 44. Transcranial direct current stimulation (tDCS) combined with cognitive emotional training (CET) as a novel treatment for depression - p. 447 61. Part V: Other aspects of treatment: Specific groups, monitoring and novel regimens - p. 456 62. Chapter 45. Putative effects of cannabidiol in depression and synaptic plasticity - p. 459 63. Chapter 46. Transcutaneous auricular vagus nerve stimulation in the treatment of depression - p. 469 64. Chapter 47. Exercise for depression as a primary and comorbid with obesity disorder: A narrative - p. 477 65. Chapter 48. Acupressure and depression: A scientific narrative - p. 489 66. Potential beneficial effects of Bifidobacterium breve A1 on cognitive impairment and psychiatric disorders - p. 497 67. Coenzyme Q10 and depression - p. 505 68. Chapter 51. Gene expression in major depressive disorder: Peripheral tissue and brain-based studies - p. 518 69. Chapter 52. Electroconvulsive therapy for depression: Effectiveness, cognitive side-effects, and mechanisms of action - p. 527 70. Chapter 53. Prenatal depression and offspring DNA methylation - p. 537 71. Chapter 54. Treating depression with theta burst stimulation (TBS) - p. 549 72. Part I: Genetic aspects of depression - p. 552 73. Chapter 1. Epigenetics in depression - p. 3 74. Chapter 2. Genes, depression, and nuclear DNA - p. 3 75. Chapter 3. Gene expression in depression: Molecular aspects of postpartum depression - p. 3 76. Genetics and epigenetics of the SLC6A4 gene in depression - p. 32 77. Chapter 5. Molecular basis of tryptophan metabolism disorders associated with depression - p. 43 78. Chapter 6. Metalloproteinases genes and their relationship with depression - p. 53 79. Chapter 7. Linking gene regions jointly with environment and depression - p. 69 80. Part II: Molecular and cellular effects of depression - p. 69 81. Chapter 8. Linking depression, mRNA translation, and serotonin - p. 69 82. Chapter 9. Changes in cortical gene expression in major depressive disorders: More evidence implicating inflammatory-related pathways in disease etiology - p. 88 83. FKBP5 gene expression as a biomarker for treatment outcome in depression - p. 99 84. Chapter 11. Neuroimaging a cytokine storm by transducing IL-1α to hippocampal cornu ammonis: COVID-19 SARS-CoV-2 - p. 99 85. Chapter 12. Linking interleukin-6 and depression - p. 99 86. Chapter 13. The role of inflammatory signaling in comorbid depression and epilepsy - p. 120 87. Chapter 14. Brain inflammasomes in depression - p. 130 88. Chapter 15. Inflammatory factors and depression in substance use disorder - p. 130 89. Chapter 16. Linking Huntington disease, brain-derived neurotrophic factor, and depressive-like behaviors - p. 156 90. Chapter 17. Depression and the NMDA receptor/NO/cGMP pathway - p. 175 91. Chapter 18. Translocator protein (18 kDa TSPO) binding in depression - p. 184 92. Chapter 19. Axonal transport proteins: What they are and how they relate to depressive behaviors - p. 194 93. Chapter 20. Molecular features of adenylyl cyclase isoforms and cAMP signaling: A link between adenylyl cyclase 7 and depression - p. 204 94. Chapter 21. Neurobiology of depression: The role of glycogen synthase kinase 3 - p. 204 95. Chapter 22. Sortilin/neurotensin receptor-3 and its derived peptides in depression - p. 204 96. Chapter 23. Implication of Wnt/beta-catenin signaling and its components in depression and neuropsychiatric disorders - p. 204 97. Chapter 24. The prefrontal cortex in depression: Use of proteomics - p. 251 98. Part III: Neurological and imaging features - p. 261 99. Chapter 25. How brain single photon emission computed topography imaging informs the diagnosis and treatment of mood disorders - p. 261 100. Chapter 26. Resting-state functional magnetic resonance imaging (rsfMRI) in bipolar and unipolar depression - p. 280 101. Chapter 27. Linking amygdala blood oxygenation-level-dependent (BOLD) activity and frontal EEG in depression - p. 282 102. Chapter 28. The rostromedial tegmental nucleus: Features and links with alcohol and depression - p. 282 103. Chapter 29. Human serotonergic neurons, selective serotonin reuptake inhibitor (SSRI) resistance and major depressive disorder - p. 282 104. Chapter 30. Role of nesfatin-1 in major depression - p. 324 105. Chapter 31. Impact of NGF signaling on neuroplasticity during depression: Insights in neuroplasticity-dependent therapeutic approaches - p. 324 106. Chapter 32. Inherited depression and psychological disorders and mental illness by germ cells and their memory - p. 344 107. Part IV: Behaviour and psychopathological effects - p. 356 108. Chapter 33. Cognitive function and neurocognitive deficits in depression - p. 356 109. Chapter 34. Cognitive and interpersonal contributors to relationship distress and depression: A review of the dyadic partner-schema model - p. 356 110. Chapter 35. Cognitive vulnerability to depression in adolescence - p. 381 111. Chapter 36. Determining the cognitive performance in the first episode of depression - p. 381 112. Chapter 37. Body image and depression - p. 392 113. Chapter 38. Sleep, anxiety, and depression - p. 400 114. Chapter 39. Depression, anxiety, and quality of life - p. 412 115. Chapter 40. Reward processing and depression: Current findings and future directions - p. 422 116. Chapter 41. Sexual functioning in depression - p. 422 117. Part V: Diet, nutrition and botanicals - p. 422 118. Chapter 42. Linking dietary glycemic index and depression - p. 422 119. Chapter 43. Gut microbiota and depression - p. 458 120. Chapter 44. Linking dietary methyl donors, maternal separation, and depression - p. 468 121. Convolvulus pluricaulis usage and depression - p. 468 122. Antidepressant activity of Crocus sativus L. and its main constituents: A review - p. 490 123. Chapter 47. Mechanisms of action of herbal antidepressants - p. 490 124. Chapter 48. Antidepressant-like effects and mechanisms of the herbal formula Xiaochaihutang in depression - p. 515 125. Part VI: Resources - p. 515 126. Chapter 49. Recommended resources on the neuroscience of depression: Genetics, cell biology, neurology, behavior, and diet - p. 515 127. Index for Volume 1 - p. 553 128. Index for Volume 2 - p. 564
The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behaviour and Diet is a comprehensive reference to the aspects, features and effects of depression. This book provides readers with the behavior and psychopathological effects of depression, linking anxiety, anger and PSTD to depression. Readers are provided with a detailed outline of the genetic aspects of depression including synaptic genes and the genome-wide association studies (GWAS) of depression, followed by a thorough analysis of the neurological and imaging techniques used to study depression. This book also includes three full sections on the various effects of depression, including diet, nutrition and molecular and cellular effects. The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behaviour and Diet is the only resource for researchers and practitioners studying depression.
The Neuroscience of Depression: Features, Diagnosis and Treatment
The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behaviour and Diet
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Contributors for Volume 1 - p. xix 7. Foreword for Volume 1 - p. xxv 8. Preface for Volume 1 - p. xxvi 9. Copyright - p. xxvi 10. Contributors for Volume 2 - p. xvii 11. Foreword for Volume 2 - p. xviii 12. Preface for Volume 1 - p. xxiv 13. Part I: Depression: Introductory chapters - p. xxiv 14. Chapter 1. Clinical staging in depression - p. 8 15. Chapter 2. Neurodevelopmental theory of depression - p. 13 16. Chapter 3. Depression after pregnancy - p. 21 17. Chapter 4. Modeling maternal depression during pregnancy: Rodent models of major depressive disorder with peripartum onset - p. 33 18. Chapter 5. Depression in mothers and mental health in their children: Impact, risk factors, and interventions - p. 45 19. Chapter 6. The neuroscience of depression: Mechanisms and treatments - p. 57 20. Chapter 7. Depression in disasters and traumatic events - p. 72 21. Chapter 8. Depression and associated Alzheimer’s disease - p. 79 22. Chapter 9. Comorbidities of depression and Parkinson’s disease - p. 89 23. Chapter 10. Understanding the relationship between depression and alcohol among students - p. 101 24. Chapter 11. Depression in obesity - p. 115 25. Chapter 12. Heart rate variability and depression - p. 121 26. Chapter 13. Neuroinflammation and depression - p. 131 27. Chapter 14. Interlinking antidepressants and the immune system - p. 143 28. Part II: Biomarkers and diagnosis - p. 151 29. Chapter 15. Assessment scoring tools of depression - p. 155 30. Chapter 16. The Beck depression inventory: Uses and applications - p. 165 31. Chapter 17. Hamilton depression rating scale: Uses and applications - p. 176 32. Chapter 18. The patient health questionnaire (PHQ) - p. 185 33. Chapter 19. Screening for antenatal depression (AND) using self-report questionnaires: Conceptual issues and measurement limitations - p. 195 34. Chapter 20. Edinburgh postnatal depression scale: Description and applications - p. 205 35. Chapter 21. The death depression scale: Description and applications - p. 211 36. Chapter 22. The Depression Anxiety Stress Scale: Features and applications - p. 219 37. Chapter 23. Arabic version of the two-question quick inventory of depression (QID-2-AR): Description and applications - p. 229 38. Chapter 24. Depression and biomarkers of cardiovascular disease - p. 239 39. Chapter 25. Thioredoxin as an antioxidant protein as a marker in depression - p. 249 40. Chapter 26. Methods of neuroimaging in depression: Applications to resting-state functional connectivity - p. 264 41. Chapter 27. Neural markers of depression in MRI - p. 271 42. Part III: Pharmacological treatments for depression - p. 279 43. Chapter 28. Angiotensin receptor 1 blockade as an antidepression strategy - p. 283 44. Chapter 29. The link between cannabinoids and depression - p. 293 45. Chapter 30. Agomelatine: Profile and applications to depression - p. 301 46. Chapter 31. Bumetanide and use in depressive states - p. 309 47. Chapter 32. Linking citalopram, serotonin reuptake inhibitors, and depressed pregnant women - p. 325 48. Chapter 33. Citalopram and its use in sleep-deprivation-induced depression - p. 337 49. Chapter 34. Monoaminergic system and antidepressants - p. 345 50. Chapter 35. Duloxetine usage in depression - p. 357 51. Chapter 36. Escitalopram and blonanserin as antidepressant agents linking in neurotrophic mechanisms - p. 369 52. (2R,6R)-Hydroxynorketamine as a novel antidepressant and its role in the antidepressant actions of (R,S)-ketamine - p. 385 53. Linking 5-hydroxytryptamine to antidepressant actions of (R)-ketamine and social stress model - p. 393 54. Chapter 39. Mirtazapine: Multitarget strategies for treating substance use disorder and depression - p. 401 55. Part IV: Counselling, psychotherapy and behavioural treatments for depression - p. 410 56. Chapter 40. Mindfulness-based cognitive therapy and depression - p. 413 57. Chapter 41. Online programs for depression - p. 423 58. Chapter 42. Clay art therapy on emotion regulation: Research, theoretical underpinnings, and treatment mechanisms - p. 431 59. Chapter 43. Solution-focused counseling and its use in postpartum depression - p. 443 60. Chapter 44. Transcranial direct current stimulation (tDCS) combined with cognitive emotional training (CET) as a novel treatment for depression - p. 447 61. Part V: Other aspects of treatment: Specific groups, monitoring and novel regimens - p. 456 62. Chapter 45. Putative effects of cannabidiol in depression and synaptic plasticity - p. 459 63. Chapter 46. Transcutaneous auricular vagus nerve stimulation in the treatment of depression - p. 469 64. Chapter 47. Exercise for depression as a primary and comorbid with obesity disorder: A narrative - p. 477 65. Chapter 48. Acupressure and depression: A scientific narrative - p. 489 66. Potential beneficial effects of Bifidobacterium breve A1 on cognitive impairment and psychiatric disorders - p. 497 67. Coenzyme Q10 and depression - p. 505 68. Chapter 51. Gene expression in major depressive disorder: Peripheral tissue and brain-based studies - p. 518 69. Chapter 52. Electroconvulsive therapy for depression: Effectiveness, cognitive side-effects, and mechanisms of action - p. 527 70. Chapter 53. Prenatal depression and offspring DNA methylation - p. 537 71. Chapter 54. Treating depression with theta burst stimulation (TBS) - p. 549 72. Part I: Genetic aspects of depression - p. 552 73. Chapter 1. Epigenetics in depression - p. 3 74. Chapter 2. Genes, depression, and nuclear DNA - p. 3 75. Chapter 3. Gene expression in depression: Molecular aspects of postpartum depression - p. 3 76. Genetics and epigenetics of the SLC6A4 gene in depression - p. 32 77. Chapter 5. Molecular basis of tryptophan metabolism disorders associated with depression - p. 43 78. Chapter 6. Metalloproteinases genes and their relationship with depression - p. 53 79. Chapter 7. Linking gene regions jointly with environment and depression - p. 69 80. Part II: Molecular and cellular effects of depression - p. 69 81. Chapter 8. Linking depression, mRNA translation, and serotonin - p. 69 82. Chapter 9. Changes in cortical gene expression in major depressive disorders: More evidence implicating inflammatory-related pathways in disease etiology - p. 88 83. FKBP5 gene expression as a biomarker for treatment outcome in depression - p. 99 84. Chapter 11. Neuroimaging a cytokine storm by transducing IL-1α to hippocampal cornu ammonis: COVID-19 SARS-CoV-2 - p. 99 85. Chapter 12. Linking interleukin-6 and depression - p. 99 86. Chapter 13. The role of inflammatory signaling in comorbid depression and epilepsy - p. 120 87. Chapter 14. Brain inflammasomes in depression - p. 130 88. Chapter 15. Inflammatory factors and depression in substance use disorder - p. 130 89. Chapter 16. Linking Huntington disease, brain-derived neurotrophic factor, and depressive-like behaviors - p. 156 90. Chapter 17. Depression and the NMDA receptor/NO/cGMP pathway - p. 175 91. Chapter 18. Translocator protein (18 kDa TSPO) binding in depression - p. 184 92. Chapter 19. Axonal transport proteins: What they are and how they relate to depressive behaviors - p. 194 93. Chapter 20. Molecular features of adenylyl cyclase isoforms and cAMP signaling: A link between adenylyl cyclase 7 and depression - p. 204 94. Chapter 21. Neurobiology of depression: The role of glycogen synthase kinase 3 - p. 204 95. Chapter 22. Sortilin/neurotensin receptor-3 and its derived peptides in depression - p. 204 96. Chapter 23. Implication of Wnt/beta-catenin signaling and its components in depression and neuropsychiatric disorders - p. 204 97. Chapter 24. The prefrontal cortex in depression: Use of proteomics - p. 251 98. Part III: Neurological and imaging features - p. 261 99. Chapter 25. How brain single photon emission computed topography imaging informs the diagnosis and treatment of mood disorders - p. 261 100. Chapter 26. Resting-state functional magnetic resonance imaging (rsfMRI) in bipolar and unipolar depression - p. 280 101. Chapter 27. Linking amygdala blood oxygenation-level-dependent (BOLD) activity and frontal EEG in depression - p. 282 102. Chapter 28. The rostromedial tegmental nucleus: Features and links with alcohol and depression - p. 282 103. Chapter 29. Human serotonergic neurons, selective serotonin reuptake inhibitor (SSRI) resistance and major depressive disorder - p. 282 104. Chapter 30. Role of nesfatin-1 in major depression - p. 324 105. Chapter 31. Impact of NGF signaling on neuroplasticity during depression: Insights in neuroplasticity-dependent therapeutic approaches - p. 324 106. Chapter 32. Inherited depression and psychological disorders and mental illness by germ cells and their memory - p. 344 107. Part IV: Behaviour and psychopathological effects - p. 356 108. Chapter 33. Cognitive function and neurocognitive deficits in depression - p. 356 109. Chapter 34. Cognitive and interpersonal contributors to relationship distress and depression: A review of the dyadic partner-schema model - p. 356 110. Chapter 35. Cognitive vulnerability to depression in adolescence - p. 381 111. Chapter 36. Determining the cognitive performance in the first episode of depression - p. 381 112. Chapter 37. Body image and depression - p. 392 113. Chapter 38. Sleep, anxiety, and depression - p. 400 114. Chapter 39. Depression, anxiety, and quality of life - p. 412 115. Chapter 40. Reward processing and depression: Current findings and future directions - p. 422 116. Chapter 41. Sexual functioning in depression - p. 422 117. Part V: Diet, nutrition and botanicals - p. 422 118. Chapter 42. Linking dietary glycemic index and depression - p. 422 119. Chapter 43. Gut microbiota and depression - p. 458 120. Chapter 44. Linking dietary methyl donors, maternal separation, and depression - p. 468 121. Convolvulus pluricaulis usage and depression - p. 468 122. Antidepressant activity of Crocus sativus L. and its main constituents: A review - p. 490 123. Chapter 47. Mechanisms of action of herbal antidepressants - p. 490 124. Chapter 48. Antidepressant-like effects and mechanisms of the herbal formula Xiaochaihutang in depression - p. 515 125. Part VI: Resources - p. 515 126. Chapter 49. Recommended resources on the neuroscience of depression: Genetics, cell biology, neurology, behavior, and diet - p. 515 127. Index for Volume 1 - p. 553 128. Index for Volume 2 - p. 564
